| 1 | Cyanocobalamin | - | [4] D00166 D00166
D03615 D03615
D03616 D03616
D03617 D03617 💬 |
- |
- |
006 [5] 6 , 13, 201, 229, 299 💬 |
| 2 | Homocysteine | Diagnostic test: methionine/homocysteine dosage [2] Diagnostic test: methionine/homocysteine dosage; Homocysteine; | - |
- |
- |
229 [1] 229 💬 |
| 3 | Methionine | C11-methionine [9] C11-methionine; Diagnostic test: methionine/homocysteine dosage; L-methionine; L-methionine ([11c]methyl); Methionine; Other: [11c]-methionine pet/mri; S-adenosyl-l-methionine; S-adenosyl-methionine (same) capsules; [11c]-methionine; | [2] D00019 D00019
D04983 D04983 💬 |
- |
- |
034 [7] 34, 75, 84, 93, 229, 298, 300 💬 |
| 4 | Molgramostim | Molgramostim [4] Molgramostim; Molgramostim 300 mcg nebuliser solution; Molgramostim nebuliser solution 300 mcg; Molgramostim nebulizer solution; | [1] D05066 D05066 💬 |
[1] CSF2RA 💬 |
Cytokine-cytokine receptor interaction [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
229 [2] 229, 299 💬 |
| 5 | Pioglitazone | Actos (pioglitazone) [6] Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | [2] D00945 D00945
D08378 D08378 💬 |
[1] PPARG 💬 |
AMPK signaling pathway [9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
002 [17] 2 , 6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
| 6 | Regramostim | - | [1] D05712 D05712 💬 |
[1] CSF2RA 💬 |
Cytokine-cytokine receptor interaction [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
229 [1] 229 💬 |
| 7 | Rituximab | Abatacept, rituximab or tocilizumab [67] Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Abp 798 biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Double-blind rituximab; Dr. reddy’s rituximab (drl_ri) 100mg; Dr. reddy’s rituximab (drl_ri) 500mg; Eltrombopag combining rituximab; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Prednisone, low dose rituximab; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (inn: rituximab), brand name in the us; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (eu); Rituximab (genetical recombination); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab (us); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Sait101 (rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab; [rituximab]; | [1] D02994 D02994 💬 |
[1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
011 [47] 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
| 8 | Sargramostim | Gm-csf (granulocyte-macrophage colony-stimulating factor, sargramostim) [4] Gm-csf (granulocyte-macrophage colony-stimulating factor, sargramostim); Gm-csf [leukine (sargramostim)]; Sargramostim; Sargramostim (leukine); | [1] D05803 D05803 💬 |
[1] CSF2RA 💬 |
Cytokine-cytokine receptor interaction [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
006 [7] 6 , 28, 60, 62, 96, 229, 285 💬 |